Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NCT: NCT06329570 · SUSPENDED
광고
NCT IDNCT06329570
상태SUSPENDED
시작일2024-10-22
완료2028-03-31
SponsorNaviFUS Corporation (INDUSTRY)
First posted
Last updated
간략 요약
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.
공식 출처
ClinicalTrials.gov에서 보기 →데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.